SUTRO BIOPHARMA, INC. Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
SUTRO BIOPHARMA, INC. (STRO) reported Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent of -22.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance · last filed 2026-03-23
- SUTRO BIOPHARMA, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2025 was -22.10%.
- SUTRO BIOPHARMA, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2024 was -26.70%.
- SUTRO BIOPHARMA, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2023 was -41.20%.
- SUTRO BIOPHARMA, INC. effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent for fiscal 2022 was -26.20%.
| Period end | Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent 12 month |
|---|---|
| 2025-12-31 | -22.10% 10-K · filed 2026-03-23 |
| 2024-12-31 | -26.70% 10-K · filed 2026-03-23 |
| 2023-12-31 | -41.20% 10-K · filed 2025-03-13 |
| 2022-12-31 | -26.20% 10-K · filed 2025-03-13 |
| 2021-12-31 | -24.70% 10-K · filed 2024-03-25 |
| 2020-12-31 | -34.70% 10-K · filed 2023-03-30 |
| 2019-12-31 | -22.70% 10-K · filed 2022-02-28 |
| 2018-12-31 | -32.70% 10-K · filed 2021-03-18 |
| 2017-12-31 | 20.80% 10-K · filed 2020-03-16 |
| 2016-12-31 | 53.00% 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |